Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world data
Our results support the potential advantages in using LA CAB + RPV in PWH with adherence issues and comorbidities.
Authors
- G Cavazza
- Roberto Rossotti (ORCID: https://orcid.org/0000-0003-4965-8789)
- Nicholas Brian Bana (ORCID: https://orcid.org/0009-0009-6467-3697)
- Alberto Borghetti (ORCID: https://orcid.org/0000-0002-7910-021X)
- Stefano Rusconi (ORCID: https://orcid.org/0000-0002-0375-9990)
- Federico D’Amico (ORCID: https://orcid.org/0000-0001-7825-4922)
- Francesca Lombardi (ORCID: https://orcid.org/0000-0001-5757-8346)
- Pierluigi Francesco Salvo (ORCID: https://orcid.org/0000-0001-7559-7364)
- Gianmaria Baldin (ORCID: https://orcid.org/0000-0003-4623-9976)
- Gabriele Pagani (ORCID: https://orcid.org/0000-0002-1668-7543)
- Dario Bernacchia (ORCID: https://orcid.org/0000-0002-0707-7348)
- Valentina Iannone (ORCID: https://orcid.org/0000-0002-0751-8836)
- Simona Di Giambenedetto
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Pisa (IT)
- University of Milan (IT)
- Agostino Gemelli University Polyclinic (IT)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Azienda Ospedaliera Ospedale Civile di Legnano (IT)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1186/s12879-025-10499-0
- Citations
- 7
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 9.77